A Phase 4 interventional study of Inhaled treprostinil in Pulmonary Arterial Hypertension, sponsored by United Therapeutics. Completed at 15 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2013-02-20.
Sponsored by United Therapeutics · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies testing treprostinil in Pulmonary Arterial Hypertension — 3 open to participants now, 5 under way, 2 of them phase 3. treprostinil · Pulmonary Arterial Hypertension.
Among the 44 studies testing treprostinil in Pulmonary Arterial Hypertension, this one is the 9th largest by enrollment, is one of 4 that started in 2008, is one of 14 in phase 4, and was the 9th registered.
700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.
Browse Pulmonary Arterial Hypertension studies →3 of the 44 studies testing treprostinil in Pulmonary Arterial Hypertension are open now, in 1 country. Recruiting first, the newest first:
Liquidia Technologies, Inc. · Sites in United States
Ages 18–80
University of Arizona · Sites in United States
Ages 18+
Shanghai Zhongshan Hospital
Ages 18–75
By country, each count listing its studies:
treprostinil: first FDA approval 2002 (REMODULIN), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 4 started in 2008.
This study's enrollment of 73 is above the median of 40 across 478 interventional studies indexed under Pulmonary Arterial Hypertension.
Median enrollment 32 across the 44 interventional studies. Of the 32 that completed or were terminated, 20 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 44 have an industry lead sponsor. The 10 most frequent:
United Therapeutics is the lead sponsor of 85 studies on the registry; 8 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 15 (88%) have results posted.
51 studies in Pulmonary Arterial Hypertension by United Therapeutics: 1 open now, 3 under way, 1 of them phase 3. Of 40 finished, 28 (70%) have results posted.
Among the 51 studies in Pulmonary Arterial Hypertension by United Therapeutics, this one is the 11th largest by enrollment of the 45 interventional ones that give a count, is one of 3 that started in 2008, is one of 11 in phase 4, and was the 8th registered.
United Therapeutics’s Pulmonary Arterial Hypertension studies by the year they started, since 2002.
1 of the studies testing treprostinil in Pulmonary Arterial Hypertension that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07759804Liquidia Technologies, Inc.A Study of Inhaled Treprostinil (LIQ861) in Adults With Pulmonary Arterial Hypertension Transitioning From Oral Selexipag | 2027-05 |
Add it to your calendar (.ics) → With an account.
Among the 44 studies testing treprostinil in Pulmonary Arterial Hypertension, from their registry updates:
Among United Therapeutics’s 51 in Pulmonary Arterial Hypertension:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a 24-month, multi-center, prospective, open-label, safety evaluation in PAH subjects following transition from a stable dose of inhaled iloprost (Ventavis).
Subjects are to be evaluated for safety throughout the course of the study while secondary assessments will be conducted at Baseline, Week 6, Week 12, and Months 6, 12, 18 and 24 following initiation of treprostinil sodium.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Solution for oral inhalation treprostinil (0.6 mg/mL). Inhaled via an ultrasonic nebulizer which provides a dose of 6mcg of treprostinil per breath. Doses are titrated up to 12 breaths four times daily.
Drug: Inhaled treprostinil
Also known as: Tyvaso
Number of Adverse Events
Overall safety of transitioning from inhaled iloprost to inhaled treprostinil was assessed by type and frequency of adverse events.
Time frame: up to 24 months
Six-minute Walk Distance (6MWD)
Change in 6MWD from Baseline to Week 12. The 6-minute walk test (6MWT) was conducted at Baseline (10-30 minutes following the last dose of inhaled iloprost) and at Week 12 (10-60 minutes following the dose of inhaled treprostinil). The change in distance (meters) between Baseline and Week 12 is reported below.
Time frame: Baseline and 12 weeks
Quality of Life (QoL) Assessment: Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR)
Change in CAMPHOR Scores from Baseline to Week 12. The CAMPHOR is a health related quality of life instrument validated for pulmonary hypertension that assesses impairment (symptoms), disability (activities) and quality of life. The questionnaire is divided into three sections; Symptoms (Scores 0-25; high scores indicate more symptoms), Activity (Score 0-30; low score indicates good functioning)and Quality of Life (0-25; high scores indicate poor QoL). The sum of these scores equates to the Total score (0-80). In the CAMPHOR scores, lower scores indicate improvements.
Time frame: Baseline and 12 weeks
Treatment Satisfaction Questionnaire of Medication (TSQM)
Change in TSQM score from Baseline to Week 12. The TSQM is a validated instrument (Health and Quality of Life Outcomes 2004, 2:12) that measures major dimensions of patient satisfaction with medications. The questionnaire is comprised of 15 questions which fall into one of four categories; Effectiveness, Side-Effects, Convenience, and Global Satisfaction. Responses are scaled on a seven point bipolar scale from 'Extremely Satisfied' to 'Extremely Dissatisfied' where higher scores indicate improvements (total scores from 0-100). The questionnaire was completed at Baseline and Week 12. The Baseline questionnaire focused on the subject's satisfaction with inhaled iloprost treatment, while the questionnaire completed at Week 12 focused on the subject's satisfaction with inhaled treprostinil.
Time frame: Baseline and 12 weeks
Patient Impression of Change
The patient impression of change (PIC) was three single therapy-related questions related to the subjects overall impression of the transition from inhaled iloprost to inhaled treprostinil. Subjects were surveyed related to their overall impression of the transition from inhaled iloprost to inhaled treprostinil at Week 12.
Time frame: Baseline and 12 weeks
N-terminal Prohormone of Brain Natriuretic Peptide (NT-proBNP)
Change in NTpro-BNP from Baseline to Week 12. Blood samples were collected for plasma NTpro-BNP analysis during the study.
Time frame: Baseline and Week 12
World Health Organization (WHO) Functional Class
Change in WHO Functional Class (FC) from Baseline to Week 12. Data presented as percent of subjects who either improved FC, worsened FC, or had no change in FC from Baseline to Week 12.
Time frame: Baseline and 12 Weeks
Drug Administration Activities Questionnaire
Change in tasks from Baseline to Week 12. At Baseline and Week 12, subjects provided information related to the daily administration and time requirements of inhaled iloprost (Baseline) and inhaled treprostinil (Week 12).
Time frame: Baseline and 12 weeks
Recruitment began 09-Dec-2008 and ended 09-Mar-2010. All recruitment took place in medical clinic settings.
| Milestone | Inhaled Treprostinil |
|---|---|
| Started | 73 |
| Completed | 65 |
| Not completed | 8 |
| Withdrew: Adverse event | 3 |
| Withdrew: Withdrawal by subject | 3 |
| Withdrew: Death | 1 |
| Withdrew: Disease progression | 1 |
Overall safety of transitioning from inhaled iloprost to inhaled treprostinil was assessed by type and frequency of adverse events.
| number of events | Inhaled Treprostinil |
|---|---|
| Overall events | 440 |
| Possibly or Probably related events | 266 |
| Severe events | 41 |
| Serious events | 15 |
Change in 6MWD from Baseline to Week 12. The 6-minute walk test (6MWT) was conducted at Baseline (10-30 minutes following the last dose of inhaled iloprost) and at Week 12 (10-60 minutes following the dose of inhaled treprostinil). The change in distance (meters) between Baseline and Week 12 is reported below.
| meters | Inhaled Treprostinil |
|---|---|
| Week 12 | 392.5 (220 to 708) |
| Change from Baseline | 16 ± 78 |
Change in CAMPHOR Scores from Baseline to Week 12. The CAMPHOR is a health related quality of life instrument validated for pulmonary hypertension that assesses impairment (symptoms), disability (activities) and quality of life. The questionnaire is divided into three sections; Symptoms (Scores 0-25; high scores indicate more symptoms), Activity (Score 0-30; low score indicates good functioning)and Quality of Life (0-25; high scores indicate poor QoL). The sum of these scores equates to the Total score (0-80). In the CAMPHOR scores, lower scores indicate improvements.
| units on a scale | Inhaled Treprostinil |
|---|---|
| Symptom Score at Week 12 | 5.3 (0 to 21) |
| Change in Symptom Score | -2.9 ± 3.9 |
| Activity Score at Week 12 | 6.6 (0 to 16) |
| Change in Activity Score | -1.2 ± 2.5 |
| Quality of Life Score at Week 12 | 4.9 (0 to 20) |
| Change in Quality of Life Score | -2.4 ± 3.9 |
| Total Score at Week 12 | 16.8 (0 to 53) |
| Change in Total Score | -6.4 ± 7.7 |
Change in TSQM score from Baseline to Week 12. The TSQM is a validated instrument (Health and Quality of Life Outcomes 2004, 2:12) that measures major dimensions of patient satisfaction with medications. The questionnaire is comprised of 15 questions which fall into one of four categories; Effectiveness, Side-Effects, Convenience, and Global Satisfaction. Responses are scaled on a seven point bipolar scale from 'Extremely Satisfied' to 'Extremely Dissatisfied' where higher scores indicate improvements (total scores from 0-100). The questionnaire was completed at Baseline and Week 12. The Baseline questionnaire focused on the subject's satisfaction with inhaled iloprost treatment, while the questionnaire completed at Week 12 focused on the subject's satisfaction with inhaled treprostinil.
| units on a scale | Inhaled Treprostinil |
|---|---|
| Effectiveness Score at Week 12 | 81.9 (44 to 100) |
| Change in Effectiveness Score | 19.9 ± 21.5 |
| Side-effects Score at Week 12 | 84.4 (25 to 100) |
| Change in Side-Effects Score | -0.5 ± 21.3 |
| Convenience Score at Week 12 | 83.3 (33 to 100) |
| Change in Convenience Score | 38.3 ± 25.9 |
| Global Satisfaction Score at Week 12 | 81.9 (36 to 100) |
| Change in Global Satisfaction | 20.0 ± 23.7 |
The patient impression of change (PIC) was three single therapy-related questions related to the subjects overall impression of the transition from inhaled iloprost to inhaled treprostinil. Subjects were surveyed related to their overall impression of the transition from inhaled iloprost to inhaled treprostinil at Week 12.
| percentage of patients | Inhaled Treprostinil |
|---|---|
| Improvement of Symptoms | 73 ± 80.5 |
| Improvment in Time Spent | 91 |
| Overall Satisfaction | 94 |
Change in NTpro-BNP from Baseline to Week 12. Blood samples were collected for plasma NTpro-BNP analysis during the study.
| pg/mL | Inhaled Treprostinil |
|---|---|
| N-terminal Prohormone of Brain Natriuretic Peptide (NT-proBNP) | -74 (-4728 to 3837) |
Change in WHO Functional Class (FC) from Baseline to Week 12. Data presented as percent of subjects who either improved FC, worsened FC, or had no change in FC from Baseline to Week 12.
| percentage of subjects | Inhaled Treprostinil |
|---|---|
| Improvement | 6 |
| No Change | 87 |
| Worsened | 7 |
Change in tasks from Baseline to Week 12. At Baseline and Week 12, subjects provided information related to the daily administration and time requirements of inhaled iloprost (Baseline) and inhaled treprostinil (Week 12).
| minutes | Inhaled Treprostinil |
|---|---|
| Week 12 Total Daily Dosing Time | 39.1 ± 25.1 |
| Change in Time Total Daily Dosing Time | -79.3 ± 80.5 |
Collected over up to 56 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Inhaled Treprostinil | — | 10/73 (13.7%) | 71/73 (97.3%) |
| Event | Inhaled Treprostinil |
|---|---|
| PneumoniaInfections and infestations | 2/73 |
| Pulmonary hypertensionCardiac disorders | 2/73 |
| Cor pulmonaleCardiac disorders | 1/73 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 1/73 |
| Atrial fibrillationCardiac disorders | 1/73 |
| DehydrationMetabolism and nutrition disorders | 1/73 |
| gastrointestinal hemorrhageGastrointestinal disorders | 1/73 |
| InfluenzaInfections and infestations | 1/73 |
| Myocardial infarctionCardiac disorders | 1/73 |
| Sick sinus syndromeCardiac disorders | 1/73 |
| Event | Inhaled Treprostinil |
|---|---|
| CoughRespiratory, thoracic and mediastinal disorders | 54/73 |
| HeadacheNervous system disorders | 32/73 |
| NauseaGastrointestinal disorders | 22/73 |
| Chest discomfortGeneral disorders | 12/73 |
| upper respiratory tract infectionInfections and infestations | 11/73 |
| nasopharyngitisRespiratory, thoracic and mediastinal disorders | 11/73 |
| flushingVascular disorders | 11/73 |
| dizzinessNervous system disorders | 10/73 |
| palpitationsCardiac disorders | 9/73 |
| throat irritationRespiratory, thoracic and mediastinal disorders | 9/73 |
| Age, Categorical(Participants) | Inhaled Treprostinil |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 63 |
| >=65 years | 10 |
| Age Continuous(years) | Inhaled Treprostinil |
|---|---|
| Mean | 49.4 ± 12.6 |
| Sex: Female, Male(Participants) | Inhaled Treprostinil |
|---|---|
| Female | 57 |
| Male | 16 |
| Region of Enrollment(participants) | Inhaled Treprostinil |
|---|---|
| United States | 73 |
| Pulmonary Arterial Hypertension (PAH) etiology(participants) | Inhaled Treprostinil |
|---|---|
| Idiopathic PAH or familial PAH | 35 |
| Connective Tissue Diseases (CTD) | 16 |
| Congenital heart disease (CHD)-repaired shunt | 4 |
| CHD-unrepaired shunt | 15 |
| HIV | 3 |
| Background PAH therapy(participants) | Inhaled Treprostinil |
|---|---|
| None | 3 |
| Endothelin receptor antagonist (ERA) | 19 |
| Phosphodiesterase-5 inhibitor (PDE-5i) | 8 |
| ERA and PDE-5i | 43 |
| Six-minute walk distance (6MWD)(meters) | Inhaled Treprostinil |
|---|---|
| Median | 378 ± 78 |
| N-terminal prohormone brain natriuretic peptide (NT-proBNP)(pg/mL) | Inhaled Treprostinil |
|---|---|
| Median | 626 (26 to 8324) |
The record gives a start of Sep 2008, a primary completion of Mar 2010 and a completion of Dec 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2013, 2 years 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Treprostinil
Pulmonary Arterial Hypertension →